Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares IssuedShares OutstandingShares Outstanding
Ratios

Syndax Pharmaceuticals (SNDX) Leases (2019 - 2026)

Syndax Pharmaceuticals (SNDX) has disclosed Leases for 8 consecutive years, with $1.2 million as the latest value for Q1 2026.

  • For Q1 2026, Leases fell 32.7% year-over-year to $1.2 million; the TTM value through Mar 2026 reached $1.2 million, down 32.7%, while the annual FY2025 figure was $1.3 million, 33.63% down from the prior year.
  • Leases hit $1.2 million in Q1 2026 for Syndax Pharmaceuticals, down from $1.3 million in the prior quarter.
  • Across five years, Leases topped out at $2.0 million in Q4 2024 and bottomed at $756000.0 in Q3 2024.
  • Average Leases over 5 years is $1.3 million, with a median of $1.2 million recorded in 2024.
  • Year-over-year, Leases surged 154.26% in 2023 and then crashed 56.33% in 2024.
  • Syndax Pharmaceuticals' Leases stood at $1.0 million in 2022, then skyrocketed by 43.12% to $1.5 million in 2023, then skyrocketed by 35.98% to $2.0 million in 2024, then tumbled by 33.63% to $1.3 million in 2025, then decreased by 9.69% to $1.2 million in 2026.
  • According to Business Quant data, Leases over the past three periods came in at $1.2 million, $1.3 million, and $1.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.